AZD9550 + AZD9550 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Steatohepatitis
Conditions
Non-alcoholic Steatohepatitis
Trial Timeline
May 2, 2023 → Nov 13, 2023
NCT ID
NCT05848440About AZD9550 + AZD9550 + Placebo
AZD9550 + AZD9550 + Placebo is a phase 1 stage product being developed by AstraZeneca for Non-alcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05848440. Target conditions include Non-alcoholic Steatohepatitis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05848440 | Phase 1 | Completed |
Competing Products
20 competing products in Non-alcoholic Steatohepatitis